GleamWall
中文EN

TELO Telomir Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1971532 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY51.3%
TTM EPS YoY-159.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-96.3%
ROA-91.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5.1%
Debt / equity0.00x
Current ratio19.60x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$251,887$444,674$467,797$1.30M$759,525$42,839$336,996$269,083
SG&A expense$493,309$1.32M$573,539$838,472$386,951$5.03M$1.85M$2.64M
Operating income——————$2.19M—
Interest expense$1,908$3,028$1,255—$0$1,342$46-$1
Net income-$705,225-$1.72M-$990,947-$2.06M-$1.10M-$5.07M-$2.18M-$2.90M
EPS (basic)-0.01-0.79-0.03—-0.03-0.17-0.07—
EPS (diluted)-0.01-0.79-0.03—-0.03-0.17-0.07—
Weighted avg. shares (diluted)68.77M60.84M34.38M—32.40M30.01M29.76M—
Balance sheet
Cash & equivalents$4.52M$5.17M$5.56M$7.29M$7.33M$754,323$402,999$1.27M
Current assets$4.64M$5.37M$5.79M$7.34M$7.40M$829,611$491,188$1.32M
Total assets$4.64M$5.37M$5.79M$7.34M$7.40M$829,611$491,188$1.32M
Current liabilities$236,746$332,424$827,310$1.43M$422,807$348,388$652,294$680,968
Total liabilities$236,746$332,424$827,310$1.43M$422,807$348,388$652,294$680,968
Shareholders' equity$4.40M$5.03M$4.96M$5.91M$6.98M$481,223-$161,105$643,037
Shares outstanding68.77M68.77M34.38M34.38M33.83M30.51M29.76M29.76M
Cash flow statement
Operating cash flow-$586,439-$1.01M-$1.77M-$1.20M-$927,264-$696,445-$863,132-$605,808
Financing cash flow-$68,143$622,107$47,351$1.16M$7.50M——$1.04M
Stock-based compensation$65,344$198,734$39,803-$7,949$98,142$4.66M$1.38M$2.06M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.